Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.

ABSTRACT: Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of this B-cell malignancy. These new drugs have often been evaluated together and in combination with older agents. However, even these novel combinations eventually become ineffective; and, thus, novel therapeutic approaches are necessary to help overcome resistance to these treatments. Recently, the Janus Kinase (JAK) family of tyrosine kinases, specifically JAK1 and JAK2, has been shown to have a role in the pathogenesis of MM. Preclinical studies have demonstrated a role for JAK signaling in direct and indirect growth of MM and downreg

SUBMITTER: Del Dosso A 

PROVIDER: S-EPMC10852065 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature